SCHEMBL12079679

SCHEMBL12079679

Cc1cc(-c2ccn(C[C@@H](C)N)n2)ccc1C#N

nearest known ligand 0.49

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AR P10275 19/20 0.49
EGLN2 Q96KS0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1817052 1.00 AR (0.49) AREGLN2
SCHEMBL1817051 1.00 AR (0.49) AREGLN2
SCHEMBL1813547 0.86 AR (0.57) AR
SCHEMBL1812528 0.86 AR (0.57) AR
SCHEMBL1812527 0.86 AR (0.57) AR
SCHEMBL27933986 0.86 CYP11B1 (0.45) AR
Hydrochloric Acid SCHEMBL28330704 0.85 AR (0.56) AR
Hydrochloric Acid SCHEMBL28330705 0.85 AR (0.56) AR
SCHEMBL12080051 0.83 AR (0.48) AR
SCHEMBL1838871 0.83 AR (0.48) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 EP disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 EP disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 EP disclosed
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2020-09-24 US disclosed
US-10711013-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2020-07-14 US disclosed
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2019-04-04 US disclosed
US-10118933-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2018-11-06 US disclosed
EP-3369732-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2018-09-05 EP disclosed
US-20170260206-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2017-09-14 US disclosed
US-9657003-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2017-05-23 US disclosed
EP-3056485-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2016-08-17 EP disclosed
CN-102596910-B Androgen receptor modulating compounds ORION CORP. (FI) 2015-11-25 CN disclosed
CN-105061313-A Androgen receptor modulating compounds ORION CORP 2015-11-18 CN disclosed
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION 2015-07-23 US disclosed
US-8975254-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2015-03-10 US disclosed
EP-2493858-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2014-07-02 EP disclosed
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-09-06 US disclosed
CN-102596910-A Androgen receptor modulating compounds ORION CORP 2012-07-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260206-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG AR 1/4885EGLN2 2169/4885
US-10118933-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG AR 1/4885EGLN2 2169/4885
US-10711013-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG AR 1/4885EGLN2 2169/4885
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG AR 1/4885EGLN2 2169/4885
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG AR 1/4885EGLN2 2169/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG AR 1/4885EGLN2 2169/4885
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG AR 1/4885EGLN2 2169/4885
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG AR 1/4885EGLN2 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.